NCT00137800 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients


Sponsors: Dana-Farber Cancer Institute Massachusetts General Hospital Brigham and Women's Hospital Genentech	Phases: Phase II
Indications	Acronym:
Non-Small-Cell Lung Carcinoma
Age Groups: Senior	Gender: Both
Names: Drug: OSI-774 (Tarceva)	Enrollment: 80

Additional information about NCT00137800.